Summary. We investigated the effects of 3 days treatment with acetazolamide 250 mg three times daily on kidney function in 8 Type 1 (insulin-dependent) diabetic patients with nephropathy, and in 7 healthy subjects in a doubleblind placebo controlled cross-over study. Glomerular filtration rate and extracellular fluid volume were measured with the single injection 5tCr-EDTA technique and fluid flow rate from the proximal tubules was determined by measurement of the renal lithium clearance. A 24% decline in glomerular filtration rate was observed in both groups during acetazolamide treatment (control subjects: 108 + 11 vs 82 + 9 ml/min, p<0.02, diabetic patients: 71-+19 vs 54+14ml/min, p <0.01). The renal lithium clearance (ml/min) remained about the same (control subjects: 22 -+ 6 vs 27 + 8, NS, diabetic patients: 14_+ 5 vs 15 + 4, NS). Absolute proximal tubular reabsorption of water (ml/min) was reduced by about onethird (control subjects: 85+11 vs 56-+7, p<0.02, diabetic patients: 55 + 17 vs 37+ 6, p < 0.02), and fractional proximal reabsorption of water and sodium (%) declined (control subjects: 79 + 5 vs 67_+ 8, p <0.02, diabetic patients: 79 + 5 vs 72_+ 6, p < 0.02). Renal sodium clearance and distal fractional reabsorption of sodium was unclmnged. Extracellular fluid volume declined by 10% in both groups (p<0.02). Albuminuria and fractional albumin clearance decreased significantly in the nephropathic patients (p < 0.02). Our study suggests that the effects of acetazolamide on kidney function are similar in healthy subjects and patients with diabetic nephropathy.